胸膜间皮瘤的免疫治疗：当前和新兴的治疗策略。
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies.
机构信息
University Hospitals Seidman Cancer Center, Cleveland, OH 44106, USA.
School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
出版信息
Int J Mol Sci. 2024 Oct 9;25(19):10861. doi: 10.3390/ijms251910861.
Abstract
Pleural mesothelioma is a rare malignancy associated with asbestos exposure and very poor prognosis, with a 5-year overall survival of 12%. Outcomes may vary according to stage at time of diagnosis and histologic subtype. Most recently, clinical trials utilizing dual checkpoint inhibitor regimens and chemotherapy in combination with immune oncologic agents have demonstrated impactful changes in outcomes. In this article, we review studies that have led to the successful implementation of immunotherapy in clinical practice for the treatment of this disease and highlight ongoing clinical trials exploring the use of different immunotherapy strategies for the treatment of pleural mesothelioma. We also discuss the challenges of immunotherapy-based approaches in the context of mesothelioma and future strategies currently being investigated to overcome them.
摘要
胸膜间皮瘤是一种罕见的恶性肿瘤，与石棉暴露有关，预后极差，5 年总生存率为 12%。结果可能因诊断时的分期和组织学亚型而异。最近，利用双重检查点抑制剂方案和化疗联合免疫肿瘤药物的临床试验表明，对结果产生了重大影响。在本文中，我们回顾了导致免疫疗法在临床实践中成功应用于治疗这种疾病的研究，并强调了正在进行的临床试验，这些试验探讨了不同的免疫治疗策略在治疗胸膜间皮瘤中的应用。我们还讨论了免疫疗法在间皮瘤中的应用所面临的挑战，以及目前正在研究的克服这些挑战的未来策略。
相似文献
1
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies.胸膜间皮瘤的免疫治疗：当前和新兴的治疗策略。
Int J Mol Sci. 2024 Oct 9;25(19):10861. doi: 10.3390/ijms251910861.
2
Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.恶性胸膜间皮瘤中的免疫检查点抑制剂：前景与挑战
Expert Rev Anticancer Ther. 2016 Jul;16(7):673-5. doi: 10.1080/14737140.2016.1191951. Epub 2016 May 30.
3
Immunotherapy for advanced and recurrent malignant pleural mesothelioma.恶性胸膜间皮瘤的晚期和复发性免疫治疗。
Cochrane Database Syst Rev. 2024 Sep 18;9(9):CD014720. doi: 10.1002/14651858.CD014720.
4
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.恶性胸膜间皮瘤中的免疫反应和免疫治疗干预。
Cancer Immunol Immunother. 2011 Nov;60(11):1509-27. doi: 10.1007/s00262-011-1103-6. Epub 2011 Sep 13.
5
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.将 PD-L1 抑制剂阿特珠单抗与 WT1/DC 疫苗联合用于上皮样恶性胸膜间皮瘤患者的标准一线治疗：Immuno-MESODEC 研究方案。
PLoS One. 2024 Jul 15;19(7):e0307204. doi: 10.1371/journal.pone.0307204. eCollection 2024.
6
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?恶性胸膜间皮瘤的系统治疗方法：化疗、靶向药物及免疫治疗有哪些新进展？
Tumori. 2016 Jan-Feb;102(1):18-30. doi: 10.5301/tj.5000436. Epub 2015 Oct 14.
7
Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.恶性胸膜间皮瘤的免疫治疗。现状与展望。
Am J Respir Cell Mol Biol. 2014 May;50(5):870-5. doi: 10.1165/rcmb.2013-0472TR.
8
Is there a role for immunotherapy in malignant pleural mesothelioma?免疫疗法在恶性胸膜间皮瘤中的作用如何？
Med Oncol. 2018 May 29;35(7):98. doi: 10.1007/s12032-018-1156-x.
9
New therapeutic strategies for malignant pleural mesothelioma.恶性胸膜间皮瘤的新治疗策略
Biochem Pharmacol. 2017 Jan 1;123:8-18. doi: 10.1016/j.bcp.2016.07.012. Epub 2016 Jul 16.
10
CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.CheckMate 743：恶性胸膜间皮瘤的一线希望
Clin Lung Cancer. 2021 Mar;22(2):71-73. doi: 10.1016/j.cllc.2020.11.009. Epub 2020 Dec 2.
引用本文的文献
1
Targeting Eukaryotic Elongation Factor 1A: How Small-Molecule Inhibitors Suppress Tumor Growth via Diverse Pathways.靶向真核生物延伸因子1A：小分子抑制剂如何通过多种途径抑制肿瘤生长。
Int J Mol Sci. 2025 Jul 29;26(15):7331. doi: 10.3390/ijms26157331.
本文引用的文献
1
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.随机试验评估 anetumab ravtansine 联合 pembrolizumab 对比 pembrolizumab 治疗间皮瘤的效果。
Lung Cancer. 2024 Sep;195:107928. doi: 10.1016/j.lungcan.2024.107928. Epub 2024 Aug 13.
2
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.将 PD-L1 抑制剂阿特珠单抗与 WT1/DC 疫苗联合用于上皮样恶性胸膜间皮瘤患者的标准一线治疗：Immuno-MESODEC 研究方案。
PLoS One. 2024 Jul 15;19(7):e0307204. doi: 10.1371/journal.pone.0307204. eCollection 2024.
3
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study.树突状细胞负载同种异体肿瘤细胞裂解物联合最佳支持治疗与单纯最佳支持治疗在化疗后作为间皮瘤患者维持治疗中的比较（DENIM）：一项多中心、开放标签、随机、2/3 期研究。
Lancet Oncol. 2024 Jul;25(7):865-878. doi: 10.1016/S1470-2045(24)00191-8. Epub 2024 Jun 4.
4
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.广泛胸膜切除术和化疗与单纯化疗治疗胸膜间皮瘤（MARS 2）：一项 3 期随机对照试验。
Lancet Respir Med. 2024 Jun;12(6):457-466. doi: 10.1016/S2213-2600(24)00119-X. Epub 2024 May 10.
5
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.UV1 端粒酶疫苗联合伊匹单抗和纳武单抗二线治疗胸膜间皮瘤的 II 期随机试验。
Eur J Cancer. 2024 May;202:113973. doi: 10.1016/j.ejca.2024.113973. Epub 2024 Mar 1.
6
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.培格非尼酶联合一线化疗治疗非上皮样胸膜间皮瘤患者：ATOMIC-Meso 随机临床试验。
JAMA Oncol. 2024 Apr 1;10(4):475-483. doi: 10.1001/jamaoncol.2023.6789.
7
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream.间皮瘤的免疫治疗：一个由来已久的治疗梦想的不断变化。
Front Immunol. 2024 Jan 8;14:1333661. doi: 10.3389/fimmu.2023.1333661. eCollection 2023.
8
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.一项评估抗 LAG-3 单克隆抗体 ieramilimab 联合抗 PD-1 单克隆抗体 spartalizumab 治疗晚期实体瘤患者的 II 期、多中心、开放标签研究。
Oncoimmunology. 2023 Dec 20;13(1):2290787. doi: 10.1080/2162402X.2023.2290787. eCollection 2024.
9
Deletions of and Detected by Copy-Number Variation Array Are Associated with Loss of p16 and MTAP Protein in Pleural Mesothelioma.通过拷贝数变异阵列检测到的 和 的缺失与胸膜间皮瘤中p16和MTAP蛋白的缺失相关。
Cancers (Basel). 2023 Oct 13;15(20):4978. doi: 10.3390/cancers15204978.
10
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.靶向 PD-1 和 LAG-3 的双特异性分子替西利珠单抗治疗实体瘤和血液系统恶性肿瘤的 1 期临床试验。
Nat Med. 2023 Nov;29(11):2814-2824. doi: 10.1038/s41591-023-02593-0. Epub 2023 Oct 19.
Zotero 插件